Faes Farma
- Company typePublic
- Founded1930
- HeadquartersMadrid, Spain
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Faes Farma firmographics
Firmographics- Name
- Faes Farma
- Legal name
- FAES FARMA, S.A.
- Website
- https://faesfarma.com
- Company type
- Public
- Founded year
- 1930
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Faes Farma industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414), Farm Supplies Merchant Wholesalers (42491)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support) (AFADALAO)
- akta.pro secondary industries
- Antimicrobials & Anti-infectives (HLAMAEAE), Livestock & Pasture Supply Retail (Feed Supplements, Animal Health Inputs) (AFABAJAJ), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)
Keywords
Where Faes Farma is headquartered
LocationHeadquarters
- HQ city
- Madrid
- HQ country
- Spain
- HQ region
- Europe
Offices7 records
Markets served
Faes Farma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Products: Development, production and commercialization of medications for allergies, gastrointestinal, immunological and pain diseases through direct sales in Iberia and international markets
- Healthcare Products: Dermo-cosmetics, dietetics, nutrition and OTC products sold through pharmacies and retail channels
- Animal Nutrition: Nutritional solutions and strategies for sustainable animal production under brands Ingaso Farm, Tecnovit and ISF by FARM Faes
- Licensing: Out-licensing of proprietary molecules like Bilastina to partners such as Pfizer, Taiho for international markets including Japan, USA, Mexico and others
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Pharmaceutical products distributed through pharmacies |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Faes Farma product offering
Product offeringCore offering
Faes Farma researches, manufactures, and commercializes pharmaceutical products for human health, including proprietary molecules such as Bilastina (antihistamine), Calcifediol (vitamin D), and Mesalazine (inflammatory bowel disease), alongside ophthalmology products (via SIFI and Edol), animal nutrition feeds (Ingaso Farm, Tecnovit, ISF), and consumer healthcare/dermo-cosmetic brands (Bioregena, Alvinatur, Diafarm). Distribution is through direct sales in Iberia, Latin America, and Africa-Middle East, complemented by global out-licensing partners covering 130+ countries.
Differentiator
Problem solved
Functional benefit
Brands
- FARM Faes: Animal nutrition and health division focusing on pig farming and sustainable animal production.
- Ingaso Farm
- Tecnovit
- ISF by FARM Faes
- Alvinatur
- Bioregena
- Diafarm
Products and services
- Bilastina Proprietary antihistamine medication for the treatment of allergies, marketed by Faes Farma in Iberia, Latin America, and Africa-Middle East and out-licensed to global partners for international markets.
- Calcifediol Vitamin D analog used for treatment of vitamin D deficiency, sold under brands including Hidroxiel and Defediol and licensed to international partners.
- Mesalazine Anti-inflammatory prescription medication for inflammatory bowel disease, ulcerative colitis and Crohn's disease, sold by Faes Farma globally.
- Animal Nutrition Products (Ingaso Farm, Tecnovit, ISF by FARM Faes) Nutritional supplements and special feeds for sustainable pig production, including piglet feeding programs, marketed under the Ingaso Farm, Tecnovit and ISF by FARM Faes brands for European pig producers and integrators.
- Dermo-cosmetic and OTC Products (Bioregena, Alvinatur, Diafarm) Over-the-counter, dermo-cosmetic and consumer healthcare products including sun protection, body care (Bioregena), CBD-based skin and muscle/joint care (Alvinatur), and consumer health/pharmaceutical products (Diafarm), sold through pharmacy retail.
- Ophthalmology Portfolio (including Akantior) Ophthalmology products consolidated through the SIFI and Laboratorios Edol acquisitions, including Akantior for orphan indications such as Acanthamoeba keratitis, distributed in Iberia, Italy, and international markets.
- INMUNO-K Project New immunomodulatory drug development project based on calcifediol, financed under the HAZITEK 2025 program, targeting new immunomodulatory indications with advanced formulation technologies.
- AZZASOL (Mesalazine Monodose) Innovative oral monodose (2-4 g) formulation of mesalazine under development to simplify administration and improve adherence in ulcerative colitis patients.
- ADHEPHARM Project New anti-adhesion drug development program targeting chronic intestinal inflammation for treatment of Inflammatory Bowel Disease (IBD), part of Faes Farma's R&D pipeline.
Companies that use Faes Farma
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Faes Farma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Faes Farma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SIFI S.p.A.coreAcquisition of 100% of SIFI shares by Faes Farma, expected to close in Q3 2025. SIFI is an ophthalmic pharmaceutical company. The merger aims to enhance the ophthalmic portfolio, expand into new regions, and develop high-growth products like Akantior in USA and other orphan indications.
Scale indicators13 records
Recent moves9 records
Expansion highlights6 records
Faes Farma competitors and assessment
Company assessmentDirect peers
- Recordati: Italian mid-cap specialty pharmaceutical company with comparable revenue scale, proprietary molecule focus, and geographic diversification across Europe and emerging markets — direct SIFI neighbor makes the overlap even stronger.
- Menarini Group: Italian privately-held pharmaceutical company with comparable broad therapeutic portfolio, strong OTC franchise, and direct commercial presence across Latin America and Mediterranean regions.
- KRKA: Slovenian generic and specialty pharmaceutical company with comparable revenue tier, CEE/Iberia/Latam geographic reach, and proprietary manufacturing plus animal health adjacency through KRKA's vet subsidiary.
- Laboratorios Esteve: Spanish privately-held pharmaceutical company headquartered in Barcelona with proprietary API development, generics, and prescription drug portfolio directly comparable to Faes Farma's Iberian pharma franchise.
- Italfarmaco: Italian family-owned specialty pharmaceutical company with proprietary R&D, similar product categories (women's health, OTC, prescription), and international expansion ambitions via subsidiaries.
- Laboratorios Rovi: Madrid-based specialty and generics pharmaceutical company with comparable size (similar revenue scale), strong manufacturing footprint, and parallel OTC/specialty portfolio strategy.
- Stada Arzneimittel: European-focused generics and specialty pharmaceutical company (German HQ) with similar revenue tier, proprietary + generic portfolio mix, and aggressive M&A-driven expansion strategy.
- Almirall: Spanish specialty pharmaceutical company listed on the Spanish stock exchange with a similar Iberian base, proprietary R&D focus, and specialty pharma commercial model serving European and Latin markets.
- Nutreco (Trouw Nutrition): Global animal nutrition and feed additives company directly comparable to Faes Farma's FARM Faes / Ingaso Farm / Tecnovit franchise in pig and livestock nutritional supplements.
Broad incumbents
- Teva Pharmaceutical: Global generics and specialty pharmaceutical giant offering overlapping respiratory, GI, and immunology products; serves as Faes Farma's competitor through global distribution but at vastly larger scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Faes Farma social profiles
Digital presenceFaes Farma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Faes Farma leadership team
Management profileNumber of profiles
Profiles7 records
Faes Farma subsidiaries and ownership
Company hierarchySubsidiaries7 records
Faes Farma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Faes Farma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Faes Farma
What does Faes Farma do?
Faes Farma researches, manufactures, and commercializes pharmaceutical products for human health, including proprietary molecules such as Bilastina (antihistamine), Calcifediol (vitamin D), and Mesalazine (inflammatory bowel disease), alongside ophthalmology products (via SIFI and Edol), animal nutrition feeds (Ingaso Farm, Tecnovit, ISF), and consumer healthcare/dermo-cosmetic brands (Bioregena, Alvinatur, Diafarm). Distribution is through direct sales in Iberia, Latin America, and Africa-Middle East, complemented by global out-licensing partners covering 130+ countries.
Is Faes Farma a public or private company?
Faes Farma is a public company. It is classified as public and is currently operating.
When was Faes Farma founded?
Faes Farma was founded in 1930. It employs 1,001 to 5,000 people.
Where is Faes Farma based?
Faes Farma is headquartered in Madrid, Spain, in the Europe region.
How does Faes Farma make money?
Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are healthcare Products, animal Nutrition and licensing.
Who are Faes Farma's main competitors?
Direct peers on record are Recordati, Menarini Group, KRKA, Laboratorios Esteve, Italfarmaco, Laboratorios Rovi, Stada Arzneimittel, Almirall and Nutreco (Trouw Nutrition). Teva Pharmaceutical is listed as a broad incumbent.
Does Faes Farma have an API?
No public API is recorded for Faes Farma.
What industry is Faes Farma in?
Faes Farma's product category is Pharmaceuticals. Its primary akta.pro industry code is AFADALAO, Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support), with a secondary code of HLAMAEAE, Antimicrobials & Anti-infectives. Its NAICS code is 424210 and its SIC code is 5122.